| ASSET | YEAR | % RETURN |
|---|---|---|
Santech (STEC) | 2025 | 31,856.14% |
FiEE (FIEE) | 2025 | 1,372.48% |
NovaBay Pharmaceuticals (NBY) | 2025 | 1,346.15% |
Oncology Institute (TOI) | 2025 | 1,063.4% |
Abits (ABTS) | 2025 | 707.21% |
Diginex Limited Ordinary Shares (DGNX) | 2025 | 683.1% |
Haoxi Health Technology Limited Class A Ordinary Shares (HAO) | 2025 | 593.9% |
Lizhi (SOGP) | 2025 | 504.23% |
Dominari (DOMH) | 2025 | 445.62% |
Galecto (GLTO) | 2025 | 381.38% |
ImmunoPrecise Antibodies (HYFT) | 2025 | 343.9% |
Sol Gel Technologies (SLGL) | 2025 | 343.58% |
9F (JFU) | 2025 | 326% |
Society Pass (SOPA) | 2025 | 321.75% |
Precipio (PRPO) | 2025 | 319.34% |
Empro Group Inc Ordinary shares (EMPG) | 2025 | 307.51% |
JFB Construction Holdings Class A Common Stock (JFB) | 2025 | 304.99% |
Phoenix Asia Holdings Limited Ordinary Shares (PHOE) | 2025 | 300% |
ABVC BioPharma (ABVC) | 2025 | 261.02% |
Paramount Gold Nevada (PZG) | 2025 | 253.93% |
Gold Resource (GORO) | 2025 | 252.14% |
Vista Gold (VGZ) | 2025 | 250.53% |
Blackboxstocks (BLBX) | 2025 | 238.7% |
Tecogen (TGEN) | 2025 | 233.78% |
Armata Pharmaceuticals (ARMP) | 2025 | 232.28% |
Micro-cap stocks are treated as having a market cap of <= $300M.
